Matthew Pavao

Dr. Matthew Pavao advises public and private companies, including early stage companies, as well as research and educational institutions, on all aspects of intellectual property to maximize revenue and meet their business objectives.

Matt’s practice involves strategic counseling with respect to complex intellectual property matters. His practice focuses on cost-effective, patent prosecution and strategic counseling with an emphasis on worldwide patent acquisition, the creation and management of diverse and complex patent portfolios, business-focused due diligence in conjunction with private and public financings, M&A transactions, licensing and partnering opportunities.

Matt also advises companies in regard to third party intellectual property rights. In particular, Matt focuses on assessing patent landscapes, analyzing third-party patents, maintaining periodic patent watches on competitors, and preparing freedom to operate, non-infringement and invalidity opinions. Matt’s practice also provides offensive competitor strategies, such as oppositions before the European Patent Office, and inter partes review and post-grant proceedings before the U.S. Patent Trial and Appeal Board.

Matt has experience in a wide range of technologies, including the fields of biochemistry, organic chemistry, pharmaceuticals, drug discovery, drug delivery, oncology and cancer therapeutics, cellular and molecular biology, neurobiology, immunology and vaccine technologies, genomic and proteomic technologies, next-generation sequencing, cosmetics, dietary supplements, stem cells, RNAi, microfluidics and medical devices, with particular extensive experience with molecular diagnostics, biomarkers and oncology therapeutics.

Matt is named a leading patent lawyer by Chambers, with the publication stating, “Matt is regularly called upon by established and emerging life sciences companies to advise on patent transactions, prosecution and portfolio management.” Clients praise Matt as "a very well-rounded IP lawyer in the biotech and pharmaceutical space” noting that “he is a pleasure to interact with and has a no-nonsense approach to complex issues." Matt is also recognized by Massachusetts Super Lawyers for his experience in intellectual property law.

Prior to joining Cooley, Matt was a partner at Mintz Levin. Earlier in his career, his scientific research was directed to identifying novel biomarkers and their use in diagnostic assays for advanced breast cancer.

Matt is the author of numerous papers and abstracts on breast cancer progression and biomarkers. He has also published and been an invited speaker on intellectual property issues facing the molecular diagnostics, biomarkers and oncology industries.